Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pediatr Res ; 40(5): 723-31, 1996 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-8910938

RESUMO

To investigate the effects of lung distension and oxygenation on umbilical blood flow (UBF) and plasma prostaglandin E2 (PGE2) in relation to arousal and stimulation of breathing movements, we studied eight chronically instrumented, unanesthetized fetal sheep between 137 and 143 d of gestation. Electrocorticogram, electro-oculogram, nuchal and diaphragmatic electromyograms, arterial pH and blood gas tensions, Hb oxygen saturation, body temperature, and UBF were recorded in each fetus. Electrocorticogram, electro-oculogram, and nuchal electromyograms were used to define sleep states. No sooner than 4 d after surgery, fetal lungs were distended with 100% O2 or N2 in a randomized order via an in situ Y-endotracheal tube. PGE2 concentrations were analyzed by RIA. A significant increase in fetal arousal and stimulation of breathing during nonrapid eye movement sleep was observed during lung distension with O2 as compared with control periods and lung distension with nitrogen. In all sleep states, UBF significantly decreased during oxygenation as compared with the control values. However, no significant correlation was observed between the time of the onset of arousal and the decrease in UBF. Lung distension with N2 resulted in increased plasma PGE2 concentrations, whereas, no change was observed during oxygenation. Our data suggest that an increase in fetal partial pressure of arterial O2 leads to a decrease in UBF. However, the onset of arousal and stimulation of breathing during lung distension and oxygenation were not dependent on a decrease in plasma PGE2 concentrations.


Assuntos
Nível de Alerta , Dinoprostona/sangue , Respiração , Artérias Umbilicais/embriologia , Animais , Gasometria , Pressão Sanguínea , Temperatura Corporal , Feminino , Frequência Cardíaca , Concentração de Íons de Hidrogênio , Ovinos/embriologia , Artérias Umbilicais/fisiologia
2.
J Invest Dermatol ; 100(2 Suppl): 231S-238S, 1993 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8433013

RESUMO

Human malignant melanoma represents a difficult therapeutic challenge to both medical scientists and practicing physicians. However, the biologic uniqueness of the tumor may provide opportunities for exploitation in therapeutics. This study proposed to undertake a systemic approach to the chemotherapy of malignant melanoma based upon the uniqueness of pigment-cell metabolic pathway pertaining to conversion of tyrosine and dopa with subsequent formation of melanin by tyrosinase and its related enzymes. The sulphur homologue of tyrosine, cysteinylphenol (CP), its amine derivative, cysteaminylphenol (CAP), and their N-acetyl and alpha-methyl derivatives have been synthesized and tested in in vivo and in vitro melanocytotoxicity and antimelanoma effects. These phenolic thioethers (PTEs) and phenolic thioether amine (amides) (PTEAs), which are substrates of tyrosinase, showed significant cytotoxicity that is selective to melanocytes and melanoma cells. Most previous attempts to impair the melanin pathway as a therapeutic strategy have been of limited success because they have been directed to catecholic compounds that are unstable and insufficient in lethality at physiologically tolerable doses. By contrast, our approach relies on phenolic compounds, PTEs and PTEAs, which are more stable than catechols and become toxic only after oxidation by tyrosinase. We found PTEA as the most promising agent for the future development of chemotherapeutic agents. The possible biologic, chemical, and pharmacologic reactions of these synthetic compounds within the melanoma cells are studied and discussed.


Assuntos
Melaninas/biossíntese , Melanoma/tratamento farmacológico , Pigmentos Biológicos/biossíntese , Benzoquinonas/metabolismo , Catecóis/metabolismo , Cisteinildopa/metabolismo , Di-Hidroxifenilalanina/análogos & derivados , Di-Hidroxifenilalanina/metabolismo , Dopamina/metabolismo , Humanos , Indóis/metabolismo , Melaninas/química , Melaninas/metabolismo , Modelos Químicos , Fenol , Fenóis/metabolismo , Tirosina/metabolismo
3.
Biochem J ; 280 ( Pt 3): 721-5, 1991 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-1764036

RESUMO

Tyrosine is an essential amino acid for the initial step of melanin synthesis, yet little is known concerning its transport in melanocytes. As an important first step in the development of new anti-melanoma agents based upon chemical and pharmacological modifications of melanin synthesis, the present study characterized the transport mechanism of tyrosine in vitro using the human melanoma cell line SK-MEL 23. Several tyrosine transport systems may be involved in melanocytes: systems L and T, which transport neutral amino acids with branched or aromatic side chains, and systems A and ASC, which transport neutral amino acids with smaller side chains. In order to determine which system or combination of systems is involved in tyrosine transport in melanoma cells, studies of kinetics, Na(+)-dependence and competitive inhibition were undertaken. The Km and Vmax. for the Na(+)-independent transport system were found to be 0.164 +/- 0.016 mM and 21.6 +/- 1.1 nmol/min per mg of protein respectively. This transport was preferentially inhibited by the system L specific analogue, 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, the system T substrate tryptophan, and the sulphur homologue of tyrosine, 4-S-cysteinylphenol. Sequential addition of these inhibitors at increasing concentrations indicated that they inhibit the same transporter. Our results suggest that tyrosine transport in SK-MEL 23 melanoma cells is similar to system L transport previously characterized in other cell types. This one transport system appears to supply all the tyrosine required for both cell growth and melanin synthesis. The transport system may be subject to manipulation by melanogenic stimulating factors, making the transport of cytotoxic tyrosine analogues an important area for further study.


Assuntos
Aminoácidos Cíclicos , Cisteína/análogos & derivados , Sistemas de Liberação de Medicamentos , Melanoma/metabolismo , Tirosina/análogos & derivados , Aminoácidos/metabolismo , Transporte Biológico Ativo , Cisteína/metabolismo , Estudos de Avaliação como Assunto , Humanos , Cinética , Sódio/metabolismo , Células Tumorais Cultivadas , Tirosina/antagonistas & inibidores , Tirosina/metabolismo
4.
Pigment Cell Res ; 3(3): 146-9, 1990 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-2127097

RESUMO

A phenolic amine compound, 4-S-cysteaminylphenol (4-S-CAP), was found to cause a selective destruction of follicular melanocytes. It was also recently found that 4-S-CAP can be a substrate for both tyrosinase and plasma monoamine oxidase (MAO). Both of these enzymes are capable of producing cytotoxic intermediates through their interaction with 4-S-CAP. To study the mechanism of selective melanocytotoxicity of phenolic amine compounds, we compared the in vivo depigmenting potency of 4-S-CAP and its three analogues; i.e., 4-S-HomoCAP, alpha-methyl(Me)-4-S-CAP and N,N-dimethyl(DiMe)-4-S-CAP, using black hair follicles. All four of these phenolic amine compounds possessed depigmenting potency. In this study we examined the kinetics of tyrosinase and MAO by these four compounds. 4-S-CAP and 4-S-HomoCAP were the substrates of both tyrosinase and MAO, whereas alpha-Me-4-S-CAP and N,N-DiMe-4-S-CAP were the substrates of tyrosinase alone. The rate of o-quinone formation by tyrosinase was not in parallel to the in vivo depigmenting potency of the tested compounds. It is therefore indicated that plasma MAO is not the enzyme directly responsible for the production of the melanocytotoxic intermediates from the phenolic amine compounds. We also found that the observed in vivo depigmentation results from complex processes involving the amount of o-quinone formed and the intracellular interaction of o-quinone with protein species.


Assuntos
Antineoplásicos/metabolismo , Cisteamina/metabolismo , Monoaminoxidase/metabolismo , Monofenol Mono-Oxigenase/metabolismo , Animais , Antineoplásicos/farmacologia , Ácido Ascórbico/farmacologia , Basidiomycota , Linhagem Celular , Cisteamina/farmacologia , Cinética , Melanócitos/efeitos dos fármacos , Melanócitos/metabolismo , Melanoma/enzimologia , Camundongos , Camundongos Endogâmicos C57BL , Oxirredução/efeitos dos fármacos , Pigmentação/efeitos dos fármacos , Quinonas/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA